However, it is also possible that there may be a ceiling effect for the cholinergic mechanism or that insufficient acetylcholine remains at the synapses in mild-to-moderate AD patients to allow a modulator the opportunity to achieve its effect, in which case different results could theoretically be observed in patients at an earlier stage of the disease

However, it is also possible that there may be a ceiling effect for the cholinergic mechanism or that insufficient acetylcholine remains at the synapses in […]

Continue reading

Merck has recently published a press release about the final analysis of the phase III trial KEYNOTE-240 (“type”:”clinical-trial”,”attrs”:”text”:”NCT02702401″,”term_id”:”NCT02702401″NCT02702401) evaluating pembrolizumab placebo while second-line treatment in European population; even though co-primary endpoints OS and PFS were improved, these differences did not meet the statistical significance

Merck has recently published a press release about the final analysis of the phase III trial KEYNOTE-240 (“type”:”clinical-trial”,”attrs”:”text”:”NCT02702401″,”term_id”:”NCT02702401″NCT02702401) evaluating pembrolizumab placebo while second-line treatment in […]

Continue reading